DNA sequence selectivity of topoisomerases and topoisomerase poisons
- PMID: 9748568
- DOI: 10.1016/s0167-4781(98)00135-3
DNA sequence selectivity of topoisomerases and topoisomerase poisons
Abstract
Chemical agents able to interfere with DNA topoisomerases are widespread in nature, and some of them have clinical efficacy as antitumor or antibacterial drugs. Drugs which have as a target DNA topoisomerases could be divided into two categories: poisons and catalytic inhibitors. Classical topoisomerase poisons stimulate cleavage in a sequence-selective manner, yielding drug-specific cleavage intensity pattern. The mechanisms of drug interaction with DNA topoisomerases, the DNA sequence selectivity of the action of topoisomerase II poisons and the identification of structural determinants of their activity have suggested that topoisomerase II poisons may fit into a specific pharmacophore, constituted by a planar ring system with DNA intercalation or intercalation-like properties, and protruding side chains interfering with the protein side of the covalent enzyme-DNA complex. The complete definition of the diverse pharmacophores of topoisomerase II poisons will certainly be of value for the design of new agents directed to specific genomic sites, and more effective in the treatment of human cancer.
Similar articles
-
A protein-mediated mechanism for the DNA sequence-specific action of topoisomerase II poisons.Trends Pharmacol Sci. 1997 Sep;18(9):323-9. doi: 10.1016/s0165-6147(97)01095-x. Trends Pharmacol Sci. 1997. PMID: 9345851 Review.
-
Design of new anti-cancer agents based on topoisomerase poisons targeted to specific DNA sequences.Curr Med Chem Anticancer Agents. 2001 Nov;1(3):219-35. doi: 10.2174/1568011013354642. Curr Med Chem Anticancer Agents. 2001. PMID: 12678755 Review.
-
Iridoids as DNA topoisomerase I poisons.J Enzyme Inhib Med Chem. 2005 Aug;20(4):389-92. doi: 10.1080/14756360500141879. J Enzyme Inhib Med Chem. 2005. PMID: 16206835
-
Triple helix-forming oligonucleotides conjugated to indolocarbazole poisons direct topoisomerase I-mediated DNA cleavage to a specific site.Bioconjug Chem. 2001 Jul-Aug;12(4):501-9. doi: 10.1021/bc000162k. Bioconjug Chem. 2001. PMID: 11459453
-
Topoisomerase II as a target for anticancer drugs: when enzymes stop being nice.Prog Nucleic Acid Res Mol Biol. 2000;64:221-53. doi: 10.1016/s0079-6603(00)64006-0. Prog Nucleic Acid Res Mol Biol. 2000. PMID: 10697411 Review.
Cited by
-
Targeting DNA topoisomerase II in cancer chemotherapy.Nat Rev Cancer. 2009 May;9(5):338-50. doi: 10.1038/nrc2607. Epub 2009 Apr 20. Nat Rev Cancer. 2009. PMID: 19377506 Free PMC article. Review.
-
The efficacy of topoisomerase II-targeted anticancer agents reflects the persistence of drug-induced cleavage complexes in cells.Biochemistry. 2008 Nov 11;47(45):11900-8. doi: 10.1021/bi800981j. Epub 2008 Oct 16. Biochemistry. 2008. PMID: 18922022 Free PMC article.
-
Novel DNA topoisomerase IIα inhibitors from combined ligand- and structure-based virtual screening.PLoS One. 2014 Dec 9;9(12):e114904. doi: 10.1371/journal.pone.0114904. eCollection 2014. PLoS One. 2014. PMID: 25489853 Free PMC article.
-
Debulking of topoisomerase DNA-protein crosslinks (TOP-DPC) by the proteasome, non-proteasomal and non-proteolytic pathways.DNA Repair (Amst). 2020 Oct;94:102926. doi: 10.1016/j.dnarep.2020.102926. Epub 2020 Jul 10. DNA Repair (Amst). 2020. PMID: 32674013 Free PMC article. Review.
-
Combination effects of docetaxel and Doxorubicin in hormone-refractory prostate cancer cells.Biochem Res Int. 2012;2012:832059. doi: 10.1155/2012/832059. Epub 2012 Jul 1. Biochem Res Int. 2012. PMID: 22811914 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
